EN DE
Watch Amarin Corporation PLC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Amarin Corporation PLC (AMRN) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Amarin Corporation PLC stock $7.65, price $11.61, that is 34.1% below the price, quality 57 out of 100. Rating: overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Ireland

AC Amarin Corporation PLC logo Thin data Nov 6, 2026

Amarin Corporation PLC

AMRN · US
Expensive, in a downtrend

Our calculation puts a fair price 34% below what the stock costs today.

Low debt
Generates free cash flow
Quality 57/100
Revenue last quarter 42% below a year ago.
Fair value $7.65 · Overvalued
Weak Growth (revenue 5y −19.0 %/yr in USD)
Loss-making · -14.6% net margin (TTM)
Trails peers (4/12)
Narrow moat 16/100
Thin data
Watch Amarin Corporation PLC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$116.80 $8.00 Fair Value $7.65 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $8.00 – $116.80 · fair‑value band $6.79 – $8.76 · the $11.61 price screens above the $7.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.

Follow Amarin Corporation in your weekly email

Every Wednesday you see whether Amarin Corporation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.

Show moreShow less

It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers.

It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.

Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Stock analysis

Amarin Corporation PLC (AMRN) currently trades at $11.61, while our model-based Fair Value estimate is $7.65, 34% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of $20.75 per share, and 1 of the 7 models we run sit above the $11.61 price.

Bear case: the DCF Models group reads lowest at $7.65, and 6 of the 7 models stay below the price. Data coverage for this calculation is low.

Scenario range: $6.79 (bear) to $8.76 (bull), the price of $11.61 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Amarin Corporation PLC reported revenue of $214M in FY2025 versus $583M in FY2021, a compound −22.2%/yr. Reported net income was −$38.8M in FY2025.

Key figures

Market cap $245M Micro · P/S ratio 1.45 · EPS (TTM) $−0.8000 · Net margin −18.2% · Return on equity −6.0% · Return on assets (EBIT) −6.6% (5-year average) · Operating margin −28.4% · Revenue (TTM) $186M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 32% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −34%, AMRN screens richer than that median.

Fair Value models

Bear $6.79 Fair Value $7.65 Bull $8.76
Price $11.61 · Downside -34.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $6.75 $7.45 $8.32 82
Growth DCF $6.79 $7.44 $8.21 80
5Y Revenue Exit $6.83 $8.01 $9.48 74
All 7 models by family
DCF Models
FCF DCF $6.75 $7.45 $8.32 82
5Y Revenue Exit $6.83 $8.01 $9.48 74
10Y Revenue Exit $6.71 $7.65 $8.76 68
Multiples
EV/Revenue $8.71 $9.96 $11.20 54
Asset-Based
NCAV (Graham) $13.70 $20.75 $25.94 54
Growth DCF
Growth DCF $6.79 $7.44 $8.21 80
Rev-Margin DCF $6.83 $8.06 $9.38 74

Open the full fair value analysis →

Quality Score breakdown

Overall quality 57/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 10
How much profit the company makes from its sales and capital
Quality Growth 69
Are margins and returns getting better?
Cashflow 50
Do the profits arrive as real cash?
Financial strength 64
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 61
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 76
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 6 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 10/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−6.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.0%
Start year 2020 (pandemic). Over 10 years: +10.1% a year
Revenue growth 32 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3.2% (2020) → −6.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−10.9%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −12.9% a year for the price.

AMRN screens overvalued: fair value 34% below the price. Compare with Eli Lilly and Company →

Compare Amarin Corporation PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks

Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 57 · Below median
Fair Value upside −34.1% · Below median
Profitability
Return on assets −5.8% · Bottom 25%
Net margin (12 months) −14.6% · Bottom 25%
Operating margin (12 months) −28.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −42.0% · Bottom 25%
Balance sheet
Debt / equity 0.10× · Below median

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/B 0.53× · Cheapest 25%
P/S (12 months) 1.32× · Cheapest 25%
Price / free cash flow (fiscal year) 36.4× · Pricier than median
PEG 0.81× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 20
FUTURE (revenue growth)0 · sector 34
PAST (return on equity)0 · sector 41
HEALTH (low debt)95 · sector 93
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Bristol-Myers Squibb Company BMY $62.14 $75.91 +22% vs AMRN
Gilead Sciences, Inc GILD $166.89 $183.58 +10% vs AMRN
Amgen Inc AMGN $460.42 $506.31 +10% vs AMRN
Novartis AG NOVN CHF 133.08 CHF 120.24 −10% vs AMRN
AbbVie Inc ABBV $291.31 $259.62 −11% vs AMRN
Merck & Co MRK $146.73 $129.26 −12% vs AMRN
Pfizer Inc PFE $29.39 $24.87 −15% vs AMRN
Roche Holding RO CHF 400.00 CHF 326.56 −18% vs AMRN
Johnson & Johnson, JNJ $276.22 $168.85 −39% vs AMRN
Eli Lilly and Company LLY $1,354 $749.92 −45% vs AMRN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Amarin Corporation PLC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Amarin Corporation PLC Fair Value". https://www.fairvalue-calculator.com/stock/AMRN

Frequently asked questions

Is Amarin Corporation PLC (AMRN) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $7.65 versus a price of $11.61, about 34% lower (overvalued).
What is the fair value of AMRN?
Our model-based fair value for Amarin Corporation PLC is $7.65 (as of Nov 6, 2026), built from audited fundamentals. The current price: $11.61.
What is the quality score of AMRN?
Amarin Corporation PLC has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amarin Corporation PLC (AMRN)?
Our model-based price target is the fair value of $7.65 (as of Nov 6, 2026) from 7 valuation models. Cautious scenario $6.79, optimistic scenario $8.76. It is a calculation from audited fundamentals, not an analyst target.
What is the Amarin Corporation PLC stock forecast for 2026?
Our models put fair value at $7.65, about 34% lower versus a price of $11.61 (overvalued). Cautious scenario $6.79, optimistic scenario $8.76. The calculation is refreshed regularly with new filings.
What is the revenue of Amarin Corporation PLC (AMRN)?
Amarin Corporation PLC reported trailing-twelve-month revenue of about $186M (latest available figure, as of Nov 6, 2026).
What growth is priced into Amarin Corporation PLC (AMRN)?
For today's price to be fair in a discounted-cash-flow model, Amarin Corporation PLC would have to grow free cash flow by -10.9 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -19.0 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of AMRN use?
Our models discount Amarin Corporation PLC at 12.0 %: a base by market capitalisation (micro), damped by beta 0.77, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Amarin Corporation PLC that is -10.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has Amarin Corporation PLC (AMRN) delivered so far?
Over the past 5 years revenue at Amarin Corporation PLC grew -19.0 % a year. The price currently implies free-cash-flow growth of -10.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Amarin Corporation PLC (AMRN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Amarin Corporation PLC (-10.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Amarin Corporation PLC (AMRN)?
The free-cash-flow yield on the price is 2.79 %: that much free cash flow Amarin Corporation PLC produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Amarin Corporation PLC (AMRN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amarin Corporation PLC it is $7.65 per share (as of Nov 6, 2026), against a price of $11.61. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Amarin Corporation PLC stock overvalued or undervalued in 2026?
As of Nov 6, 2026, AMRN trades above its calculated fair value: price $11.61, fair value $7.65, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AMRN?
No. The price is what the market pays today ($11.61); the fair value is what the company's own numbers justify ($7.65). For Amarin Corporation PLC the two are $3.96 per share apart. That gap is exactly why we show both numbers side by side.
How much is Amarin Corporation PLC worth?
The market values Amarin Corporation PLC at about $245M (market capitalisation, as of Nov 6, 2026). Per share that is $11.61; our models calculate a fair value of $7.65 per share.
What do the bullish and bearish scenarios say about AMRN?
Our models span a range for Amarin Corporation PLC: cautious scenario $6.79, base $7.65, optimistic $8.76 per share (as of Nov 6, 2026, price $11.61). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of AMRN?
The PEG ratio of Amarin Corporation PLC is 0.81 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Amarin Corporation PLC (AMRN)?
Balance-sheet figures for Amarin Corporation PLC (as of Nov 6, 2026): return on equity −6.0%, debt of 0.10 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is AMRN from its 52-week high?
Amarin Corporation PLC trades at $11.61, about 32% below its 52-week high of $16.98 and 3% above the low of $11.32 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $7.65 is for.
Which stocks are comparable to Amarin Corporation PLC?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amarin Corporation PLC stock attractive at the current price?
The data as of Nov 6, 2026: price $11.61, calculated fair value $7.65 (−34%), Quality Score 57/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AMRN calculated?
We run Amarin Corporation PLC through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $7.65 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Amarin Corporation PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amarin Corporation PLC (AMRN)?
The closing price on Nov 6, 2026 was $11.61. Our model-based fair value is $7.65, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amarin Corporation PLC right now?
The price sits above even our optimistic bull case ($8.76). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Amarin Corporation PLC

How large is the market capitalisation of Amarin Corporation PLC (AMRN)?
The market capitalisation of Amarin Corporation PLC is $245M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Amarin Corporation PLC (AMRN)?
The price-to-sales ratio of Amarin Corporation PLC is 1.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Amarin Corporation PLC (AMRN)?
Earnings per share at Amarin Corporation PLC are $−0.8000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Amarin Corporation PLC (AMRN)?
The net margin of Amarin Corporation PLC is −18.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Amarin Corporation PLC (AMRN)?
The return on equity (ROE) of Amarin Corporation PLC is −6.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Amarin Corporation PLC (AMRN)?
On an EBIT basis the return on assets of Amarin Corporation PLC is −6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Amarin Corporation PLC (AMRN)?
The operating margin of Amarin Corporation PLC is −28.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Amarin Corporation PLC (AMRN)?
Revenue at Amarin Corporation PLC is growing −42.0% versus a year earlier (3y avg −16.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Amarin Corporation PLC (AMRN)?
Earnings per share at Amarin Corporation PLC are growing −94.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Amarin Corporation PLC (AMRN) hold?
Amarin Corporation PLC holds more cash than debt, $123M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Amarin Corporation PLC in the live analysis

One click puts Amarin Corporation PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.